Medical Xpress

NOVEMBER 7, 2022

A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly reduced circulating transthyretin (TTR) protein levels in patients with ATTR amyloid cardiomyopathy, a progressive and fatal cause of heart failure, according to late-breaking research presented today at the American Heart Association's Scientific Sessions (..)

Gene Editing 70

Gene Editing Gene Protein Research 70

STAT News

JULY 12, 2022

Somewhere in New Zealand, the first patient ever has been dosed with a kind of gene-editing treatment known as a base editor, a newer way of utilizing CRISPR for gene editing. The company studying the treatment, Verve Therapeutics, announced the news Tuesday.

Gene Editing 98

Gene Editing Gene Therapy Gene Cardiology 98

Medical Xpress

JANUARY 20, 2023

A team of researchers at the University of Texas Southwestern Medical Center has found that it is possible in mice to protect the heart from ischemia-reperfusion using the CRISPR-Cas9 gene editing system.

Gene Editing 81

Gene Editing Genomics Genome Gene 81

Scienmag

DECEMBER 3, 2020

Those two key problems – safety and efficacy – are what continue to hold CRISPR-Cas9 gene targeting back from its full clinical potential, explains co-senior author Y. Eugene Chen, M.D., […].

Gene Editing 41

Gene Editing Gene DNA Genetics 41

XTalks

SEPTEMBER 4, 2024

The data, presented at the European Society of Cardiology Congress 2024, suggest that vutrisiran could significantly reduce the risk of death and heart-related issues, marking a potential treatment breakthrough.

Trials 52

Trials RNA Protein Gene Editing 52

XTalks

AUGUST 2, 2023

Bayer’s primary focus lies in prescription products, including cardiology and women’s healthcare, along with therapeutics in oncology, hematology and ophthalmology. Additionally, Bayer has formed a partnership with Mammoth Biosciences to broaden its product portfolio with innovative gene-editing technology.

Sales 98

Sales Manufacturing FDA Approval Life Science 98